HAEMONETICS CORP — M&A Activity 2010

Feb 1, 2010

PAGEBREAK

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

xbrl,dc Date of Report (Date of earliest event reported) February 1, 2010 /xbrl,dc

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts	1-10730	04-2882273
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

400 Wood Road	02184
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))

Folio /Folio

PAGEBREAK

TOC /TOC link1 "Item 7.01 REGULATION FD DISCLOSURE"

Item 7.01 REGULATION FD DISCLOSURE

On January 31, 2010, Haemonetics Corporation (the “Company”) entered a definitive agreement under which they will acquire Global Med Technologies, Inc. for approximately $60 million in a cash tender offer.

The information in this current report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

link1 "Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS"

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1: Press Release of Haemonetics Corporation dated February 1, 2010 announcing the definitive agreement with Global Med Technologies, Inc.

Folio 2 /Folio

PAGEBREAK

link1 "SIGNATURES"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HAEMONETICS CORPORATION (Registrant)
Date: February 1, 2010	/s/ Christopher Lindop
	Christopher Lindop, Chief Financial Officer
	and VP Business Development

Folio 3 /Folio

PAGEBREAK

link1 "EXHIBIT INDEX"

EXHIBIT INDEX

99.1 Press Release issued by Haemonetics Corporation announcing agreement with Global Med Technologies, Inc. on February 1, 2010.

Folio 4 /Folio